Cited by 120Publish Year 2009Author Esther Zipperer,Daniela Pelz,Kathrin Nachtkamp,Andrea Kuendgen,Corinna Strupp,Norbert GattermanAdjusting DLCO for Hb and its effects on the Hematopoietic

The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is used to counsel patients regarding the risk of transplantation and selection of conditioning regimens.Pulmonary disease,most frequently demonstrated by a decreased diffusion capacity of carbon monoxide (DLCO),is the most prevalent comorbidity captured by the HCT-CI.Cited by 20Publish Year 2014Author Aya Nakaya,Takehiko Mori,Masatsugu Tanaka,Naoto Tomita,Chiaki Nakaseko,Shingo Yano,Shin FujisaData Management Education session - EBMTHematopoietic cell transplantation (HCT)specific comorbidity index a new tool for risk assessment before allogeneic HCT.Mohamed Sorror,Michael Maris,Rainer Storb,Frederic Baron,Brenda Sandmaier,David Maloney,Barry Storer.Cited by 20Publish Year 2017Author Mariano Berro,Jorge A.Arbelbide,Maria M.Rivas,Ana Lisa Basquiera,Gonzalo Ferini,Adriana VitriHematopoietic cell transplantation-specific comorbidity ·The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is a tool used to predict HCT outcomes in recipients of alternative donor grafts.In a report published in Biology of Blood and Marrow Transplantation,researchers described an augmented comorbidity/age index comprising the HCT-CI,age,and serum values of albumin,ferritin,and platelets that may have higher

Cited by 4Publish Year 2017Author L.Decook,Y.H.Chang,James L Slack,D.Gastineau,J.Leis,P.Noel,Jeanne Palmer,Lisa Sproat,MHematopoietic Cell Transplantation,Version 2.2020,NCCN

Overview.Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with malignant or nonmalignant hematologic disorders with the goal of re-establishing normal hematopoietic and immune function.1,2 HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies and is also used to support patients Cited by 7Publish Year 2019Author Mahmoud Elsawy,Mahmoud Elsawy,Barry E.Storer,Barry E.Storer,Filippo Milano,Filippo Milano,BrRelated searches for hematopoietic cell transplantation spehematopoietic cell transplantation comorbidity indexhematopoietic stem cell transplantation reviewallogeneic hematopoietic cell transplantationhematopoietic stem cell transplantation hscthematopoietic cell transplanttypes of hematopoietic cell transplantshematopoietic stem cell transplantnon hematopoietic cellsSome results are removed in response to a notice of local law requirement.For more information,please see here.12345NextCited by 90Publish Year 2008Author Navneet S.Majhail,Claudio G.Brunstein,Sarah McAvoy,Todd E.DeFor,Ahmed Al-Hazzouri,Daniela SeAssociation of hematopoietic cell transplantation-specific Jul 01,2017·Fingerprint Dive into the research topics of 'Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation'.Together they form a unique fingerprint.Homologous Transplantation Medicine Life Sciences

Does the Hematopoietic Cell Transplantation Specific

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical Cord Blood and Matched Related Donor Transplants Navneet S.Majhail,Claudio G.Brunstein ,Sarah McAvoy,Todd E.DeFor ,Ahmed Al-Hazzouri,Daniela Setubal,Mukta Arora ,Chap T.Le ,John E Does the Hematopoietic Cell Transplantation Specific Jul 14,2014·Thus,the evaluation of comorbidity is of increasing importance to more precisely assess the benefits and risks of the transplantation procedure.Researchers from Seattle developed the hematopoietic cell transplantationspecific comorbidity index (HCT-CI),which was associated with the risk of mortality in several retrospective studies.Patient Eligibility for Hematopoietic Cell Transplant (HCT)Three hematopoietic cell sources are used in HCT bone marrow,peripheral blood stem cells (PBSC),and umbilical cord blood.Each source in an allogeneic transplant can come from a related or unrelated donor or cord blood unit.Most autologous transplants use PBSC for ease of collection of the cells and a more rapid hematopoietic recovery.

Prognostic Performance of the Augmented Hematopoietic

·Allogeneic hematopoietic cell transplantation (HCT) is a curative therapeutic modality for most malignant and nonmalignant hematologic disorders.However,this treatment is associated with a substantial risk of subsequent nonrelapse mortality (NRM).Pretransplantation comorbidities,as evaluated by the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI),have beenThe hematopoietic cell transplantation-specific comorbidity index (HCTHematocrit

The hematocrit,also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF),is the volume percentage (%) of red blood cells in blood.It is normally 45% for men and 40% for women.It is considered an integral part of a person's complete blood count results,along with hemoglobin concentration,white blood cell count,and platelet count.The hematopoietic stem cell transplantation comorbidity We studied the impact of comorbidities on survival and evaluated the prognostic utility of comorbidity scores in MDS patients,who received best supportive care and were assessable according to the Charlson Comorbidity Index (CCI) and the Hematopoietic Stem Cell Transplantation Comorbidity Index (HCTCI) 171 patients were identified in the Duesseldorf MDS Registry.

en.wikipedia-CI)score is a useful tool to assess the risk for nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation.Although the HCT-CI has been investigated in autologous stem cell transplantation (ASCT),its use is limited.Cited by:20Publish Year:2017Hematopoietic Cell Transplantation-Specific Comorbidity

Was this helpful?Hematopoietic Cell Transplantation-Specific Comorbidity The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score is a useful tool to assess the risk for nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation.Although the HCT-CI has been investigated in autologous stem cell transplantation (ASCT),its use is limited.